Wednesday 30 December 2015

Unnatural Amino Acids - Increasing Applications in Pharmaceuticals

RI Technologies' market research study on Unnatural Amino Acids - market is driven by derivatives that find large applications in pharmaceuticals.
Optically clean unnatural amino acids are becoming more and more significant as pharmaceutically active compounds.
— Anasuya Vemuri
HYDERABAD, TELANGANA, INDIA, December 30, 2015 /EINPresswire.com/ -- RI Technologies' market researchreport on Unnatural Amino Acids gives a market insight into the different types of Unnatural Amino Acids (β-Amino Acids, β-Amino Acid Derivatives, Cyclic Amino Acids & Derivatives, D-Amino Acids, D-Amino Acid Derivatives, DL-Amino Acids, DL-Amino Acid Derivatives, L-Amino Acid Derivatives and Other ) and their application areas such as R&D, Pharmaceutical, Food & Feed, Agrochemicals and Other applications.
The study includes estimates and projections for the global Unnatural Amino Acids by type and applications. Regional Analysis is covered separately for North America (United States and Canada); Europe (UK, Germany, Switzerland, Italy, The Netherlands, and Rest of Europe; Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific); and Rest of World.

Business profiles of 57 major companies are discussed in the report. The report serves as a guide to global Unnatural Amino Acids industry covering more than1000 companies that are engaged in Unnatural Amino Acids R&D, synthesis, discovery, testing and supply of derivatives, products and services. Information related to industrial activity, corporate developments, research trends, product releases, product developments, partnerships, collaborations, and mergers and acquisitions is also covered in the report.

Research - As Good as the Methodology is!

Development of selective peptide receptor ligands with orally administered drug properties has progressed rapidly in the past decade. Non-natural amino acids are accepted major tool to prepare peptide ligand mimetics with superior biological activity and proteolytic resistance. Non-natural amino acids have applications as pharmacologically active products, molecular scaffolds, conformational constraints and building blocks. They embody an almost countless array of different structural elements to develop new therapeutic drugs. In the field of pharmaceuticals, unnatural amino acids are found to have a very important role to play. Chiral amines also have an industrial significance and importance in the fine chemical arena and this is because of their use as resolving agents, catalysts for asymmetric synthesis, and chiral bases.

About 18% of the leading drugs and agrochemicals include amino acids in their synthesis. Unnatural amino acids can make proteins 30 times more effective in treating cancer. For example, L-Homophenylalanine is an unnatural amino acid and is an effective drug for the therapy of hypertension and congestive heart diseases. Diagnostic / Therapeutic medicine are the important application area of unnatural amino acids.

Owing to the growing importance of unnatural amino acids as pharmaceutical intermediates, a range of methods are being developed for their enantiomerically pure preparation. Regularly employed processes consist of resolutions by diastereomeric crystallization, enzymatic resolution of derivatives, partition by simulated moving bed (SMB) and chiral chromatography. These methods are adopted to separate racemic mixtures but the highest hypothetical yield is expected to be around 50%.

For non-proteinogenic L-amino acids such as L-nor-valine, L-nor-leucine, L-2-amino-5-[1-3], dioxolan-2-yl-pentanoic acid, L-tert-leucine and others; the preferred method for their synthesis is enzymecatalyzed reductive aminations.
Optically clean unnatural amino acids are becoming more and more significant as pharmaceutically active compounds. Chiral directing auxiliaries, and chiral synthons are widely being used in organic synthesis. The use of D-amino acids in the production of semi-synthetic antibiotics is increasing very fast and is being widely preferred. The drugs - ampicillin and amoxicillin - are produced using D-phenylglycine and p-hydroxy-Dphenylglycine respectively. These drugs are found to be broad-based and more stable compared to enzymatic degradation than naturally occurring (benzyl) penicillin. The production quantity of p-Hydroxy-D-phenylglycine ranges in several kilotons per year.

For more information please contact us - contactus@researchimpact.com

About RI Technologies

Research Impact Technologies, www.researchimpact.com, is a premier market research provider. The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data. The reports provide strategic information tools that help to probe into and support critical business decisions. RI Technologies believes in broadening the value of market research obtained through several dedicated streams of information. Investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools stand to benefit from RI Technologies' unique market research reports.


Research Impact Technologies
Tel +91 9676994272 
Email: contactus@researchimpact.com
Anasuya Vemuri
Research Impact Technologies
+91 9676994272
email us here

Friday 4 December 2015

Biologics - Shaping the Future of Drug Discovery and Development

Biologics for rheumatic diseases, which focus on molecules concerned with the techniques connected with immune systems, offer a good option to the current treatment procedures for autoimmune diseases.
Research Impact Technologies' latest update on Biologics market provides an exclusive insight into this field of complex medications. Global Biologics market is projected to grow at 9.33% compounded annually from 2005 through 2020. Blood and blood products are the major product area with tremendous potential and growth. Automated blood collection and processing systems as well as prior-screening capabilities of latest assays are expected to enhance quantity and quality of blood. Since the last decade, the therapeutic market for monoclonal antibodies has grown exponentially. Bevacizumab, Trastuzumab, Adalimumab, Infliximab and Rituximab are the top five therapeutic antibodies available. About 40% of the best selling biopharmaceuticals are therapeutic monoclonal antibodies. Development of vaccines has proved to be crucial and effective in the pharmaceutical industry. Growing human and animal populations and advancement of science and technology are the driving factors behind the global vaccines market. High prevalence of diabetes, treatment and diagnosis rates, device penetration and changes in price are driving the human insulin market. Biologics market holds tremendous potential and promise. 

Since the approval of insulin as the first recombinant therapeutic protein, biologic therapies in drug development have gained immense significance. Biologics have delivered life changing results. Many unmet medical needs are being addressed for several disease areas using traditional replacement proteins to more recent, highly engineered antibodies, oligonucleotides, fusion proteins, and gene constructs. 

The market study analyzes the Biologics market by product type, application area and by disease area. Product types include Monoclonal Antibodies, Blood & Blood Products, Vaccines, Insulin and Other, while application areas are for both human and animal consumption. The disease areas covered include autoimmune diseases, oncology, infectious Diseases, Diabetes and other. The report serves as a guide to Biologics market, covering more than 800 companies that are engaged in Biologics products and services. Major Contract Research Organizations, Research Institutes and Universities serving the Biologics market are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to Biologic products is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, and Rest of World with more than 150 exclusive graphically represented exhibits.

This report may help Drug Developing Companies, Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to –

Identify Market Opportunities
Review and Analyze Global and Regional Markets
Gauge Market Potential for Products
Identify Competition
Use Market Research for exploring new areas
Acquire Meaningful Guidelines for Strategic Planning
Gear up for Market Entry
Get Actionable Information


To order this market research report on Biologics, please contact us atcontactus@researchimpact.com. You may also explore custom research services on Biologics with RI Technologies. 


About RI Technologies

Research Impact Technologies, www.researchimpact.com, is a premier market research provider. The company believes in pure research that will trigger action for immediate customer needs rather than plain reporting of data. The reports provide strategic information tools that help to probe into and support critical business decisions. RI Technologies believes in broadening the value of market research obtained through several dedicated streams of information. Investment banks, companies, management consultants, trade associations, corporate executives, business analysts, libraries, universities, and business schools stand to benefit from RI Technologies' unique market research reports.


contactus@researchimpact.com
Anasuya Vemuri
Research Impact Technologies
+91 9676994272